Tricholeukemia and therapeutic perspectives in a refractory case
International Journal of Development Research
Tricholeukemia and therapeutic perspectives in a refractory case
Received 02nd December, 2018; Received in revised form 14th January, 2019; Accepted 26th February, 2019; Published online 29th March, 2019
Copyright © 2019, Andressa Volkert Goulart et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Tricholeukemia, also called hairy cell leukemia, is a chronic B-cell lymph proliferative neoplasm. It is a rare, more frequent disease in males. The clinical presentation is characterized by cytopenia, splenomegaly and non-specific symptoms such as asthenia and weight loss. The diagnosis is performed by immuno-phenotyping of bone marrow by flow cytometry, and the BRAFV600V mutation is present in most cases. Therapy is usually dramatic with purine analogues and other alternatives include newer drugs such as the BRAFV600E inhibitors. The objective of this study was to report a case of tricholeukemia with onset of follow-up at Tereza Ramos Hospital, Lages SC / Brazil, between 2018 and 2019. From the analysis of this case, it was concluded that the patient presented similar findings to the literature, with a clinical presentation and marrow phenotype characteristic, but little response to two treatment lines, constituting an atypical case and, therefore, subject to in-depth analysis.
